Q32 Bio completes SIGNAL-AD Phase 2 enrollment; topline data expected Q4 2024

Q32 Bio Inc.

Enrolled 121 patients in SIGNAL-AD Phase 2 trial, exceeding original target of ~100.
Part B randomized 1:1 to bempikibart 200 mg Q2W SC or placebo for 12 weeks.
Primary endpoint: mean % change from baseline in EASI score at week 14.
SIGNAL-AA (alopecia areata) enrollment also completed; both topline data due Q4 2024.
CEO cites patient demand as driver of enrollment surpassing initial target.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.